Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) is now available.
Recordati S.p.A. has updated its share buyback program, initially communicated in April 2025, with recent transactions executed by UBS Europe SE. From July 28 to August 1, 2025, the company purchased a total of 176,283 shares at a weighted average price of 51.7557 Euros per share. As of August 1, 2025, Recordati holds 3,965,975 own shares, representing 1.896% of its share capital. This buyback is part of Recordati’s strategy to allocate shares for stock option and performance share plans aimed at management incentives.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, originating from a family-run pharmacy in Northern Italy in the 1920s. It provides therapeutic options in general and specialist medicine, including rare diseases, and is involved in clinical development, production, marketing, and licensing of active ingredients and finished products. The company operates in about 150 countries across EMEA, Americas, and APAC regions, employing over 4,580 people.
Average Trading Volume: 288,714
Technical Sentiment Signal: Buy
Current Market Cap: €10.46B
Learn more about REC stock on TipRanks’ Stock Analysis page.